Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01164735 · ClinicalTrials.gov registry record
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
A clinical trial of Recurrent Uterine Corpus Carcinoma and Stage III Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- 169
- Enrollment target
- 1
- Study location
NCT01164735: Completed study of Recurrent Uterine Corpus Carcinoma and Stage III Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group.
NCT01164735 is a study of Recurrent Uterine Corpus Carcinoma and Stage III Uterine Corpus Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 169 participants, below the 633-participant average among 7 other Recurrent Uterine Corpus Carcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01164735, a study of Recurrent Uterine Corpus Carcinoma and Stage III Uterine Corpus Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying biomarkers in tissue samples from patients with stage III, stage IV, or recurrent endometrial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Primary Outcome
The Kaplan-Meier method will be used to estimate and plot the unadjusted survival and progression-free survival time distributions by TOPO2A expression and amplification status.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2010-01 |
| Est. Completion | 2018-01 |
What the finished NCT01164735 record still lists
NCT01164735 is an observational study that tracks outcomes without assigning an intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 633-participant average among 7 other Recurrent Uterine Corpus Carcinoma trials with a reported enrollment target (73% lower).
The record links to 3 conditions, with Recurrent Uterine Corpus Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT01164735 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01164735 about?
NCT01164735 is a clinical study titled "Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer". This research study is studying biomarkers in tissue samples from patients with stage III, stage IV, or recurrent endometrial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and i...
What is the current status of trial NCT01164735?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2010-01. Estimated completion is 2018-01.
What conditions does trial NCT01164735 study?
This clinical trial studies the following conditions: Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer.
What interventions are being tested in trial NCT01164735?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01164735?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01164735 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Uterine Corpus Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
COMPLETED · Phase 2
-
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
COMPLETED · Phase 2
-
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
COMPLETED · Phase 3
-
Prognostic Biomarkers in Patients With Endometrial Cancer
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia